The 10‐year follow‐up results showed that anastrozole was more effective and safer than tamoxifen in the long‐term adjuvant treatment of postmenopausal women with ER(+) and/or PR(+) early breast cancer [105]. The gene discussed is ESR1; the disease is breast cancer.